Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP338089.RAA_52ROvIgjLAxla9vqdbd1jlejEHPU8R3LrnVYri52U130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP338089.RAA_52ROvIgjLAxla9vqdbd1jlejEHPU8R3LrnVYri52U130_provenance.
• NP817658.RAdpusm1zVtn48geb6kiGYvvAdIW-u9ECdQAYc-aUdgy8130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817658.RAdpusm1zVtn48geb6kiGYvvAdIW-u9ECdQAYc-aUdgy8130_provenance.
• NP512370.RABGrnylk66Xfo9zIcw_nW6yBQkFhKRHEjTPW2Gebzv1c130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP512370.RABGrnylk66Xfo9zIcw_nW6yBQkFhKRHEjTPW2Gebzv1c130_provenance.
• NP617278.RAQ5kITLAZDktJzMhbLr_cF676_5Rf5L7Ka3B4FWGT0_o130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP617278.RAQ5kITLAZDktJzMhbLr_cF676_5Rf5L7Ka3B4FWGT0_o130_provenance.
• assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP657138.RADNWdSrzQ019pNin9hld-tnzK6m-KJ48YeDU7twxas7M130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP657138.RADNWdSrzQ019pNin9hld-tnzK6m-KJ48YeDU7twxas7M130_provenance.
• NP629087.RAEeSxt32npqE3-OSuW9-U5HP4zeJGh6XAKJVCOCXD-u0130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP629087.RAEeSxt32npqE3-OSuW9-U5HP4zeJGh6XAKJVCOCXD-u0130_provenance.
• NP657140.RAP8SIE11-Lx46gO5DDnAgmbpDdhwnfjSZJXGnmgY1Pcs130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP657140.RAP8SIE11-Lx46gO5DDnAgmbpDdhwnfjSZJXGnmgY1Pcs130_provenance.
• NP657142.RANdH3pQA_Lc1Eo66dmqR41umzWz4kEiQCSX4pFBBAhBU130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP657142.RANdH3pQA_Lc1Eo66dmqR41umzWz4kEiQCSX4pFBBAhBU130_provenance.
• NP657143.RALG8-IdJr1pHh7j8qZ1uslgt9xz2e-FMYvppxVTtmrS0130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP657143.RALG8-IdJr1pHh7j8qZ1uslgt9xz2e-FMYvppxVTtmrS0130_provenance.
• NP896185.RAKPgaRmibFhhKXxPStsRWUiM4-2IQcgdEzp19HaYT8Wc130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP896185.RAKPgaRmibFhhKXxPStsRWUiM4-2IQcgdEzp19HaYT8Wc130_provenance.
• NP629078.RAxgKYwyXtpD-4KIdKo0B71ZxfZQBzGHdIzRgLDI2SIc8130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP629078.RAxgKYwyXtpD-4KIdKo0B71ZxfZQBzGHdIzRgLDI2SIc8130_provenance.
• NP936619.RA7Jc_kiY3H_ncZBDt1aCU6e-a8G34Q_5Or1pukUB8teY130_assertion description "[Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP936619.RA7Jc_kiY3H_ncZBDt1aCU6e-a8G34Q_5Or1pukUB8teY130_provenance.